insitro: machine learning with designated data

How insitro aims to improve machine learning-based target discovery by creating its own ‘fit-for-purpose’ data

Just 12 months after announcing the launch of insitro, AI veteran and CEO Daphne Koller has led the drug discovery and machine learning company to a series A round of over $100 million and a biopharma deal with Gilead. insitro’s core selling proposition is that it generates "fit-for-purpose" data that takes much of the noise out of machine learning-based target discovery.

Most companies using machine learning to discover targets aggregate previously collected data sets to feed into their software. These can be from genomic,

Read the full 830 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE